Sonntag, Juli 31, 2022
StartBiotechnologyNew patent for NOVO drug SAXENDA – DrugPatentWatch

New patent for NOVO drug SAXENDA – DrugPatentWatch


Copyright © DrugPatentWatch. Initially revealed at New patent for NOVO drug SAXENDA

Annual Drug Patent Expirations for SAXENDA
Annual Drug Patent Expirations for SAXENDA

Saxenda is a drug marketed by Novo and is included in a single NDA. It’s accessible from two suppliers. There are twenty-three patents defending this drug.

SAXENDA drug worth tendencies.

Drug patent litigation for SAXENDA.

This drug has thirty-eight patent members of the family in 13 international locations.

The generic ingredient in SAXENDA is liraglutide recombinant. Two suppliers are listed for this compound. Further particulars can be found on the liraglutide recombinant profile web page.

For extra info on how DrugPatentWatch can assist along with your pharmaceutical enterprise intelligence wants, contact admin@DrugPatentWatch.com or go to www.DrugPatentWatch.com

Make Higher Choices with DrugPatentWatch

» Begin Your Free Trial Immediately «

Copyright © DrugPatentWatch. Initially revealed at New patent for NOVO drug SAXENDA

RELATED ARTICLES

Most Popular

Recent Comments